Dr. Reddy's Laboratories Limited (DRREDDY) — Announcement | 7 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Dr. Reddy's terminates Novartis distribution agreement after shareholding change

Dr. Reddy's Laboratories announced termination of its distribution agreement with Novartis India effective August 7, 2026, following Novartis's change in controlling shareholding. The company will continue commercializing the affected brands until September 30, 2026, ensuring uninterrupted supply during the transition period.

📄 View Original Announcement (PDF)

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

📊 More DRREDDY filings

See all DRREDDY filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DRREDDY — Free

Free account · 2 AI queries/day